How melanoma tumours evade drug treatment
November 25th, 2010 - 5:40 pm ICT by ANILondon, Nov 25 (ANI): A new research has discovered how some melanoma tumours evade drug treatment.
The findings by the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT pinpoint a critical gene called COT (also known as MAO3K8) involved in melanoma growth provide a framework for discovering ways to tackle cancer drug resistance.
“In melanoma as well as several other cancers, there is a critical need to understand resistance mechanisms, which will enable us to be smarter up front in designing drugs that can yield more lasting clinical responses,” said senior author Levi Garraway, of Dana-Farber and Harvard Medical School.
“Our work provides an unbiased method for approaching this problem not only for melanoma, but for any tumour type,” he added.
To explore the basis of this drug resistance, Garraway and his colleagues applied a systematic approach involving hundreds of different proteins called kinases.
From this work, the researchers identified several intriguing proteins, but the one that particularly stood out was COT.
While their initial findings were noteworthy, Garraway and his co-workers sought additional proof of the role of COT in melanoma drug resistance.
They analyzed human cancer cells, searching for ones that exhibit B-RAF mutations as well as elevated COT levels. The scientists successfully identified such “double positive” cells and further showed that the cells are indeed resistant to the effects of the RAF inhibitor.
“These were enticing results, but the gold standard for showing that something is truly relevant is to examine samples from melanoma patients,” said Garraway.
Garraway and his colleagues obtained three samples for analysis and in two out of three cases, COT gene levels became elevated following RAF inhibitor treatment or the development of drug resistance.
“Although we need to extend these results to larger numbers of samples, this is tantalizing clinical evidence that COT plays a role in at least some relapsing melanomas,” added Garraway.
The study is published in the journal Nature. (ANI)
- Full genetic blueprint of multiple prostate tumors unveiled - Feb 10, 2011
- New strategy to fight cancer drug resistance discovered - Jun 21, 2010
- New hope in the fight against melanoma - Dec 14, 2010
- Zebrafish offers skin cancer clues - Apr 06, 2011
- Scientists complete whole-exome sequencing of skin cancer - Apr 16, 2011
- Combo therapy may overcome Herceptin-resistant breast cancer - Mar 14, 2011
- 'Smart' lung cancer drug shows promise - Oct 28, 2010
- Zebrafish model reveals skin cancer-promoting gene - Mar 24, 2011
- 'Penicillin' breakthrough in cancer treatment? - Sep 15, 2010
- Malaria drug 'may slow pancreatic cancer growth' - Mar 16, 2011
- Skin cancer pill showing 'remarkable' results, say researchers - Aug 26, 2010
- Skin cancer pill shrinks tumour in 80 percent cases - Aug 26, 2010
- First molecule that blocks key component of cancer genes' on-off switch created - Sep 25, 2010
- Full genetic blueprint of blood cancer offers new insights - Mar 24, 2011
- Molecular predictor of metastatic prostate cancer identified - Feb 03, 2011
Tags: cancer drug, clinical evidence, clinical responses, critical gene, critical need, dana farber cancer, dana farber cancer institute, drug resistance, farber cancer institute, gold standard, harvard medical school, human cancer cells, initial findings, melanoma, melanoma patients, mutations, raf, resistance mechanisms, systematic approach, tumours